Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 28, 2012

Filing Date
Filed February 21, 2013
Period End
December 28, 2012
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 21, 2013. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported a net loss of $147.6 milliona for 2012 and an accumulated deficit of $1.3 billion, with total revenues of $47.4 million, down from $289.6 million in 2011.

The decline reflects 2011 revenue accelerations tied to the terminated Bristol-Myers Squibb 2008 agreement ($99.1 millionb) and the terminated Sanofi collaboration ($53.1 million), with no comparable license revenue in 2012. Research and development expenses were $128.9 million and general and administrative expenses were $31.8 million for the year. The company's central event was FDA approval of COMETRIQ (cabozantinib) on November 29, 2012 for progressive, metastatic medullary thyroid cancer, with commercial launch in January 2013 at a wholesale acquisition cost of $9,900 for a 28-day supply.

The filing estimates 500 to 700 first and second line metastatic MTC patients in the United States each year who will be eligible, so the company expects only limited near-term product revenue. Development continues in metastatic castration-resistant prostate cancer (COMET-1 and COMET-2, top-line results expected in 2014), with phase 3 trials in hepatocellular and renal cell cancer planned for 2013. Balance sheet capital rose sharply in 2012.

Cash and investments were $634.0 millionc at December 31, 2012, supported by $287.5 million of 4.25% convertible notes due 2019 and a February and August 2012 equity offerings. Total debt was $335.7 million, and the company states it expects its resources to fund operations for at least 12 months following the end of 2012. Its loan and security agreement with Silicon Valley Bank requires deposit balances at 100% to 107% of outstanding principal, and the Deerfield Notes carry mandatory prepayments in 2014 and 2015.

Key Highlights

  1. FDA approved COMETRIQ (cabozantinib) on November 29, 2012 for progressive, metastatic MTC; commercial launch in January 2013 at a wholesale acquisition cost of $9,900 per 28-day supply.
  2. Total revenues were $47.4 million in 2012, versus $289.6 million in 2011, which included accelerated license revenue from terminated collaborations.
  3. Net loss of $147.6 million (basic and diluted loss of $0.92 per share) for 2012; accumulated deficit of $1.3 billion.
  4. Cash and investments of $634.0 million at December 31, 2012, following the August 2012 issuance of $287.5 million 4.25% convertible senior subordinated notes due 2019 and concurrent equity offering of 34.5 million shares at $4.25.
  5. Total debt of $335.7 million at December 31, 2012, including the Deerfield Notes and a $85.3 million Silicon Valley Bank term loan and line of credit balance.
  6. Cabozantinib pivotal program: COMET-1 and COMET-2 in metastatic CRPC with top-line results expected in 2014; phase 3 trials in hepatocellular and renal cell cancer planned for 2013.
  7. Collaboration milestone eligibility of approximately $3.1 billion on a non-risk adjusted basis; revenues in 2012 were concentrated, with Bristol-Myers Squibb at 66%, Merck at 22% and Daiichi Sankyo at 12%.

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$47.45M$289.64M−83.6%
Cost of Revenue$0$0—
Gross Profit$47.45M$289.64M−83.6%
R&D Expenses$128.88M$156.84M−17.8%
SG&A Expenses$31.84M$33.13M−3.9%
Operating Expenses$169.89M$200.10M−15.1%
Operating Income-$122.44M$89.53M−236.7%
Interest Expense$24.78M$16.26M+52.4%
Net Income-$145.34M$75.70M−292.0%
EPS (Basic)$-0.92$0.60−253.3%
EPS (Diluted)$-0.92$0.58−258.6%
Shares Outstanding (Basic)160.14M126.02M+27.1%
Shares Outstanding (Diluted)160.14M130.48M+22.7%

Frequently Asked Questions

  1. How much revenue is COMETRIQ expected to generate?

    The filing does not give a revenue forecast. It estimates 500 to 700 first and second line metastatic MTC patients in the United States each year who will be eligible for COMETRIQ, and states that the company expects to generate only limited revenues from COMETRIQ in the near term. Revenue in 2012 came almost entirely from collaboration agreements, and the company had not generated product revenue as of December 31, 2012.

  2. Does the company have enough cash to fund operations?

    The company states that its current cash and cash equivalents, short- and long-term investments, and funding expected from existing collaborators will enable it to maintain operations for at least 12 months following the end of 2012. It also says future capital requirements will be substantial and it may need to raise additional capital earlier than anticipated.

  3. What are the main debt obligations and near-term repayments?

    The 2019 Notes ($287.5 million face amount) mature August 15, 2019. The Deerfield Notes ($124.0 million initial principal) require mandatory prepayments in 2014 and 2015 equal to 15% of specified collaboration payments received in the prior year, subject to a $27.5 million annual maximum, with a $10.0 million minimum due in January 2014. The Silicon Valley Bank term loan of $80.0 million is due May 31, 2017. A $10.0 million mandatory prepayment on the Deerfield Notes was made in January 2013.

  4. When are results from the prostate cancer trials expected?

    The company believes top-line results from the COMET-1 and COMET-2 trials in metastatic castration-resistant prostate cancer will be available in 2014.

  5. Why did revenue decline so sharply in 2012?

    The filing attributes the decline primarily to 2011 acceleration of license revenue: $99.1 million from the terminated 2008 Bristol-Myers Squibb agreement for XL281 and $53.1 million from the terminated 2009 Sanofi collaboration, plus a $15.3 million termination fee accrued in December 2011. The company recognized no license revenue under those agreements in 2012.